Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 2313-2318, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bettica, P.
Right arrow Articles by Baylink, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bettica, P.
Right arrow Articles by Baylink, D. J.

Clinical Chemistry, Vol 38, 2313-2318, Copyright © 1992 by American Association for Clinical Chemistry

Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared

P Bettica, L Moro, SP Robins, AK Taylor, J Talbot, FR Singer and DJ Baylink
Jerry L. Pettis VA Hospital, Loma Linda, CA.

We compared the clinical performances of four bone-resorption (BR) assays (hydroxyproline, HYP; galactosyl hydroxylysine, GHYL; deoxypyridinoline, DPD; and pyridinoline, PYD) in subjects with different BR rates: normal (adult men and premenopausal women), mildly increased (postmenopausal osteoporotic women), high (Paget disease patients), and very high (children). The discrimination power (Z score) and the accuracy (estimated by receiver-operating characteristic analysis) for GHYL, DPD, and PYD were compared with those for HYP. Discrimination power and accuracy were similar for high- and very-high- BR groups for all four assays. However in the mildly increased-BR group, DPD, GHYL, and PYD showed a higher discrimination power and accuracy than did HYP. The clinical performances of HYP, DPD, GHYL, and PYD are comparable for large changes in BR. For modest changes, DPD, GHYL, and PYD are more accurate and have a higher discrimination power than does HYP.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
A. W. Al-Dehaimi, A. Blumsohn, and R. Eastell
Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption
Clin. Chem., May 1, 1999; 45(5): 676 - 681.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Bettica, M. Bevilacqua, T. Vago, M. Masino, E. Cucinotta, and G. Norbiato
Short-Term Variations in Bone Remodeling Biochemical Markers: Cyclical Etidronate and Alendronate Effects Compared
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3034 - 3039.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A.-M. Heikkinen, M. Parviainen, L. Niskanen, M. Komulainen, M. T. Tuppurainen, H. Kroger, and S. Saarikoski
Biochemical Bone Markers and Bone Mineral Density during Postmenopausal Hormone Replacement Therapy with and without Vitamin D3: A Prospective, Controlled, Randomized Study
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2476 - 2482.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.